THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 22, 2007--Amgen
(NASDAQ:AMGN) today announced that David Lacey, M.D., has been named
senior vice president, head of Research, effective immediately. Over
the past year, Lacey acted as the interim head of Research -- in
addition to his role as Amgen South San Francisco site leader -- and
demonstrated his ability to effectively manage Amgen´s global Research
organization, encompassing the company´s Oncology/Hematology,
Inflammation, Metabolic Disorders and Neuroscience therapeutic areas.
"David is a seasoned executive with an impressive record of
accomplishment in drug discovery and development," said Roger
Perlmutter, M.D., Ph.D., Amgen´s executive vice president, Research &
Development. "I am confident that under David´s leadership, our
world-class research organization will continue to be at the forefront
of discovering important new medicines."
Lacey´s accomplishments include serving as Amgen´s director of
Pathology where he initiated the clinical studies of KGF, which
ultimately was approved as Kepivance(R) (palifermin), the first and
only growth factor indicated to decrease the incidence and duration of
severe oral mucositis in patients with hematologic cancers undergoing
high-dose chemotherapy, with or without radiation, followed by bone
marrow transplant. The safety and efficacy of Kepivance have not been
established in patients with non-hematologic malignancies. Lacey also
played a key role in the discovery of osteoprotegerin (OPG) and helped
to elucidate the role of the RANK/RANK Ligand pathway in bone
metabolism, which led to the development of denosumab. Denosumab is an
investigational therapy for which Amgen is currently conducting
clinical trials across a wide range of bone loss conditions.
Lacey´s medical research career spans nearly 25 years and includes
experience in academia and industry. He joined Amgen in 1994 as
associate medical director in the department of Experimental
Pathology. During his 13-year career at Amgen, he has held a number of
roles with increasing responsibility within the Pathology, Oncology
and Metabolic Disorders areas of the business.
Prior to joining Amgen, Lacey served as assistant professor of
Pathology at the Jewish Hospital at Washington University Medical
Center, and before that was a postgraduate research associate in the
University of Colorado´s Department of Pathology. He obtained a
bachelor´s degree in biology and his medical degree from the
University of Colorado, graduating with Phi Beta Kappa and Alpha Omega
Alpha honors, respectively.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
Amgen remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and vital
medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
Mary Klem, (805) 447-6979 (media)
Arvind Sood, (805) 447-1060 (investors)